REG-EMA-Wegovy-7-2mg-CHMP-Opinion — CHMP Positive Opinion (Dec 12, 2025)

[DRAFT — authored 2026-04-20. Date and opinion content verified via Novo Nordisk press release 2026-04-20.]

Source

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Positive opinion on Wegovy 7.2 mg, December 12, 2025.

External URLs:

Opinion Summary

On December 12, 2025, the EMA CHMP issued a positive opinion for a new higher dose of Wegovy: semaglutide 7.2 mg once-weekly SC injection.

Indication (pending EC authorization)

Chronic weight management in adults with obesity (BMI ≥30 kg/m²) who have tolerated the 2.4 mg maintenance dose and require additional weight reduction.

Evidence Basis

STEP UP trial (Wharton S et al., Lancet Diabetes Endocrinol 2025;13(11):949-963, PMID 40961952): n=1,407 non-T2D adults; 72-week weight loss 18.7% with 7.2 mg vs 15.6% with 2.4 mg vs 3.9% placebo
STEP UP T2D trial (PMID 40961953): n=512 T2D + obesity; 72-week weight loss 13.2% with 7.2 mg

Headline Data Emphasized by CHMP and Novo Nordisk

Average 20.7% weight loss at 72 weeks in people with obesity without diabetes (from STEP UP primary cohort reporting)
1 in 3 participants achieved ≥25% weight loss at 72 weeks
84% of weight lost was fat mass — muscle function preserved (per sub-study analyses)
Safety/tolerability profile consistent with the approved 2.4 mg dose, with higher rates of GI adverse events and dysesthesia at higher dose

Next Regulatory Step

Novo Nordisk expects final authorization decision from the European Commission in early 2026. Following EC decision, Wegovy 7.2 mg will be available across EU/EEA member states.

Timing Context

EMA CHMP positive opinion: December 12, 2025
FDA approval (via National Priority Voucher Program): March 19, 2026 (~3 months later)

This timing is notable because FDA typically lags EMA on new drug approvals; in this case FDA used the accelerated NPV pathway (54-day review) to approve slightly faster than the standard EU centralized-approval timeline.

Clinical Relevance

The CHMP positive opinion establishes the EU regulatory pathway for higher-dose semaglutide and sets expectation for 2026 EU availability. Teaching points:

International prescribing parity is approximately achieved by April 2026 (FDA approved March 19, 2026; EC decision anticipated early 2026 following December CHMP opinion).
Framing the HD story: Both US and EU regulators accepted the STEP UP evidence base for the HD indication — the evidence is robust across jurisdictions.
International patients may encounter 7.2 mg availability differences depending on timing of EC decision vs EU country-level launch.

Linked Peptides

Semaglutide

Related Notes

PMID-40961952 – STEP UP Wharton Semaglutide 7.2 mg Obesity — STEP UP pivotal trial
PMID-40961953 – STEP UP T2D Lingvay Semaglutide 7.2 mg — STEP UP T2D
REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval — FDA counterpart
REG-EMA-Wegovy-SmPC-2026 – EU Summary of Product Characteristics — EU current SmPC

REG-EMA-Wegovy-7-2mg-CHMP-Opinion-2025 – CHMP Positive Opinion